Abstract
Objectives: GOG 249 was developed to determine if the combination of vaginal brachytherapy (BT) and three cycles of paclitaxel and carboplatin (PC) are superior to whole pelvic radiation therapy (WPRT) in terms of disease-free survival for high-intermediate risk (H-IR) endometrial cancer (EMCA) patients. Accordingly, we estimated the costs and outcomes of four treatment modalities used for the management of H-IR EMCA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
